| 1 | FDMT4D Molecular Therapeutics, Inc. | 100 | 230195% | -182% | $680M | — |
| 2 | XFORX4 Pharmaceuticals, Inc | 96 | 1273% | -226% | $390M | 4 |
| 3 | AUTLAutolus Therapeutics plc | 93 | 645% | -381% | $421M | 2 |
| 4 | NVAXNOVAVAX INC | 89 | 65% | -15% | $1.6B | 6 |
| 5 | MGTXMeiraGTx Holdings plc | 85 | 145% | -151% | $1.3B | — |
| 6 | IMCRImmunocore Holdings plc | 81 | 29% | -7% | $1.7B | 3 |
| 7 | ALVOAlvotech | 78 | 20% | 5% | $1.2B | — |
| 8 | CLLSCellectis S.A. | 74 | 76% | -93% | $332M | — |
| 9 | NRCNRC HEALTH | 70 | -4% | 8% | $505M | — |
| 10 | FENCFENNEC PHARMACEUTICALS INC. | 67 | -6% | -22% | $372M | — |
| 11 | STROSUTRO BIOPHARMA, INC. | 63 | 65% | -154% | $504M | — |
| 12 | IOVAIOVANCE BIOTHERAPEUTICS, INC. | 59 | 61% | -148% | $1.9B | 2 |
| 13 | VALNValneva SE | 56 | 3% | -66% | $495M | — |
| 14 | RGNXREGENXBIO Inc. | 52 | 105% | -330% | $687M | — |
| 15 | DNAGinkgo Bioworks Holdings, Inc. | 48 | -25% | -184% | $679M | — |
| 16 | EDITEditas Medicine, Inc. | 44 | 25% | -282% | $560M | — |
| 17 | CCCCC4 Therapeutics, Inc. | 41 | 1% | -292% | $475M | — |
| 18 | MESOMESOBLAST LTD | 37 | 191% | -594% | $1.9B | — |
| 19 | LCTXLineage Cell Therapeutics, Inc. | 33 | 53% | -436% | $337M | — |
| 20 | VIRVir Biotechnology, Inc. | 30 | -8% | -676% | $1.7B | 3 |
| 21 | MAZEMaze Therapeutics, Inc. | 26 | -100% | -613% | $1.7B | — |
| 22 | OCGNOcugen, Inc. | 22 | 9% | -1605% | $511M | — |
| 23 | TSHATaysha Gene Therapies, Inc. | 19 | 17% | -1738% | $1.9B | — |
| 24 | FATEFATE THERAPEUTICS INC | 15 | -51% | -2057% | $340M | — |
| 25 | DBVTDBV Technologies S.A. | 11 | 36% | -2607% | $936M | — |